Progenics Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Progenics Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed early-phase tilt upper quartile by trial count

Progenics Pharmaceuticals: 8 sponsored US clinical trials, none currently recruiting.

Progenics Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Progressive mCRPC, with 1 trials.

Upper-quartile sponsor footprint

Progenics Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 2

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689
COMPLETED Phase 3

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
COMPLETED Phase 2

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT02981368
COMPLETED Phase 2

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

NCT02020135
COMPLETED Phase 2

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT01695044
COMPLETED Phase 1

Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

NCT01414296
COMPLETED Phase 1

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

NCT01414283
COMPLETED Phase 2

Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

NCT00055185

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 1

Therapeutic Areas

Progressive mCRPC 1
Prostatic Neoplasm 1
Castration-resistant Prostate Cancer 1
Cancer of the Prostate 1
Metastatic Prostate Cancer 1
Prostate Cancer 1

How the Progenics Pharmaceuticals early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Progressive mCRPC (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Progenics Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Progenics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Progenics PharmaceuticalsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Progenics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Progenics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Progenics Pharmaceuticals page

8 registered trials is a research-attention snapshot, not an endorsement of Progenics Pharmaceuticals or any single study.

  • None of Progenics Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Progressive mCRPC is the condition Progenics Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Progressive mCRPC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Progenics Pharmaceuticals pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.